



## Antiparasitics 2023

Guest Editor:

**Prof. Dr. Marcelo J. Nieto**

Department of Pharmaceutical  
Sciences, School of Pharmacy,  
Southern Illinois University  
Edwardsville, Edwardsville, IL  
62026-2000, USA

Deadline for manuscript  
submissions:

**closed (29 February 2024)**

### Message from the Guest Editor

Dear Colleagues,

Parasitic infections affect more than two billion people worldwide and account for significant morbidity and mortality throughout the world. Antiparasitic drugs represent the main type of therapeutic treatment, but as is the case with most drugs, they have many side effects, and the risk of resistance is always a concern. Furthermore, the significant suffering and loss of productivity associated with these drugs results in a large financial burden for a population that already has limited resources. Many of the parasitic diseases are considered to be neglected tropical diseases (NTDs), as established by the World Health Organization (WHO). Most of the current antiparasitic drugs represent no financial return on investment for the pharmaceutical industry. Indeed, the development of new or novel antiparasitic drugs has been characterized by a lack of investment from the private sector and low attention from public health.

In this Special Issue of *Pharmaceuticals*, we welcome both reviews and original research articles focused on the discovery and development of new antiparasitic drugs.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)